StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
73
This year
3
Publishing Date
2023 - 10 - 17
2
2023 - 10 - 06
1
2023 - 09 - 11
1
2023 - 08 - 28
1
2023 - 08 - 16
1
2023 - 07 - 11
1
2023 - 06 - 27
1
2023 - 06 - 16
1
2023 - 05 - 22
1
2023 - 03 - 30
1
2023 - 03 - 23
1
2023 - 03 - 02
1
2023 - 02 - 13
1
2023 - 01 - 26
1
2022 - 11 - 18
1
2022 - 10 - 31
1
2022 - 10 - 24
1
2022 - 10 - 11
1
2022 - 09 - 15
1
2022 - 08 - 10
1
2022 - 07 - 29
1
2022 - 07 - 20
1
2022 - 06 - 24
2
2022 - 06 - 06
2
2022 - 06 - 02
1
2022 - 05 - 31
1
2022 - 05 - 16
1
2022 - 05 - 03
1
2022 - 04 - 11
1
2022 - 03 - 30
1
2022 - 03 - 14
1
2022 - 02 - 25
1
2022 - 02 - 16
1
2022 - 02 - 14
1
2022 - 01 - 06
1
2021 - 12 - 15
1
2021 - 12 - 06
1
2021 - 12 - 02
1
2021 - 11 - 15
1
2021 - 11 - 12
1
2021 - 11 - 08
1
2021 - 10 - 25
1
2021 - 10 - 07
1
2021 - 10 - 01
1
2021 - 09 - 17
2
2021 - 09 - 16
2
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 09 - 01
1
2021 - 07 - 19
1
2021 - 07 - 16
1
2021 - 06 - 14
1
2021 - 06 - 11
1
2021 - 06 - 10
1
2021 - 06 - 08
1
2021 - 05 - 19
1
2021 - 04 - 23
1
2021 - 03 - 25
1
2021 - 02 - 24
1
2020 - 12 - 23
1
Sector
Health technology
73
Manufacturing
1
Tags
100
1
Active
1
Advanced
2
Agreement
1
Al102
1
Alliances
3
Antibody
4
Application
1
Bbp-398
2
Benefits
3
Biocapital
2
Biotech-bay
2
Camzyos
2
Cancer
14
Car-t
2
Cel
3
Cell
7
Cell carcinoma
5
Clinical-trials-phase-i
3
Clinical-trials-phase-ii
15
Clinical-trials-phase-iii
20
Collaboration
6
Covid-19
2
Disease
2
Europe
2
Genetown
2
Immunotherapy
4
Int230
2
Iot
3
Lung
8
N/a
7
Nivolumab
21
Ongoing
3
Opdivo
19
Pharm-country
9
Pharma
2
Pharmaceutical
2
Phase 1
8
Phase 2
9
Phase 3
11
Plus
6
Positive
7
Pre-clinical
2
Preclinical
2
Program
3
Renal
6
Research
5
Response
3
Results
10
Sclerosis
2
Show
2
Solid tumors
5
Study
2
Therapeutics
5
Therapy
8
Topline
5
Treatment
12
Trial
48
Trials
2
Update
2
Entities
4d molecular therapeutics inc
24
Abb ltd
72
Abbvie inc.
62
Actinium pharmaceuticals, inc.
28
Aldeyra therapeutics, inc.
38
Alnylam pharmaceuticals, inc.
38
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Amgen inc.
25
Anavex life sciences corp.
24
Arcutis biotherapeutics, inc.
29
Arrival
26
Arrowhead pharmaceuticals, inc.
23
Astellas pharma inc
26
Astrazeneca plc
64
Beigene, ltd.
35
Biogen inc.
23
Biovie inc.
28
Bioxcel therapeutics, inc.
26
Bristol-myers squibb company
73
Clearside biomedical, inc.
24
Clene inc
25
Cnh industrial n.v.
69
Cybin inc
26
Cytokinetics, incorporated
29
Dynavax technologies corporation
28
Eli lilly and company
161
Enlivex therapeutics ltd.
26
Exelixis, inc.
28
Fortress biotech, inc.
41
Gates industrial corporation plc
25
Gilead sciences, inc.
48
Global industrial co
38
Honeywell international inc.
53
Horizon therapeutics public limited company
46
I-mab
34
Icon plc
43
Immix biopharma, inc.
26
Immutep limited
34
Incyte corporation
49
Johnson & johnson
203
Medtronic plc
25
Merck & company, inc.
72
Moleculin biotech, inc.
34
Novartis ag
34
Novo nordisk a/s
42
Ocugen, inc.
27
Orange
91
Pds biotechnology corporation
25
Pfizer, inc.
61
Plus therapeutics, inc.
35
Regeneron pharmaceuticals, inc.
44
Regenxbio inc.
29
Sanofi
311
Sellas life sciences group, inc.
24
Sorrento therapeutics, inc.
38
Stag industrial, inc.
32
Takeda pharmaceutical company limited
56
Tg therapeutics, inc.
27
Thermo fisher scientific inc
48
Symbols
ADXS
1
AMGN
2
AVEO
1
AYLA
3
BBIO
2
BLUE
1
BMY
73
BOLT
3
CGEN
2
EXEL
4
GRTS
3
IMCR
1
INTS
2
JNJ
1
KPTI
1
NKTR
3
REPL
1
SNY
1
SNYNF
1
TAK
2
TCRR
1
TSVT
2
Exchanges
Nasdaq
29
Nyse
73
Crawled Date
2023 - 10 - 18
2
2023 - 10 - 06
1
2023 - 09 - 11
1
2023 - 08 - 28
1
2023 - 08 - 16
1
2023 - 07 - 11
1
2023 - 06 - 27
1
2023 - 06 - 16
1
2023 - 05 - 22
1
2023 - 03 - 30
1
2023 - 03 - 23
1
2023 - 03 - 02
1
2023 - 02 - 14
1
2023 - 01 - 26
1
2022 - 11 - 18
1
2022 - 10 - 31
1
2022 - 10 - 24
1
2022 - 10 - 11
1
2022 - 09 - 15
1
2022 - 08 - 10
1
2022 - 07 - 29
1
2022 - 07 - 20
1
2022 - 06 - 24
2
2022 - 06 - 06
2
2022 - 06 - 02
1
2022 - 05 - 31
1
2022 - 05 - 16
1
2022 - 05 - 04
1
2022 - 04 - 11
1
2022 - 03 - 30
1
2022 - 03 - 14
1
2022 - 02 - 25
1
2022 - 02 - 16
1
2022 - 02 - 14
1
2022 - 01 - 06
1
2021 - 12 - 15
1
2021 - 12 - 06
1
2021 - 12 - 02
1
2021 - 11 - 15
1
2021 - 11 - 12
1
2021 - 11 - 08
1
2021 - 10 - 25
1
2021 - 10 - 07
1
2021 - 10 - 01
1
2021 - 09 - 17
2
2021 - 09 - 16
2
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 09 - 01
1
2021 - 07 - 19
1
2021 - 07 - 16
1
2021 - 06 - 14
1
2021 - 06 - 11
1
2021 - 06 - 10
1
2021 - 06 - 08
1
2021 - 05 - 19
1
2021 - 04 - 23
1
2021 - 03 - 25
1
2021 - 02 - 25
1
2020 - 12 - 23
1
Crawled Time
00:00
5
08:00
1
10:00
1
11:00
4
12:00
24
12:15
4
12:20
1
12:30
2
13:00
5
13:15
1
13:20
1
14:00
3
14:30
1
15:00
2
15:20
1
16:00
2
17:00
3
18:00
4
19:00
1
20:00
2
21:00
1
22:00
2
23:00
2
Source
www.biospace.com
66
www.globenewswire.com
7
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
entities :
Bristol-myers squibb company
save search
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published:
2024-03-28
(Crawled : 22:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-7.72%
|
O:
0.26%
H:
2.03%
C:
1.57%
first
disease
active
update
trial
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published:
2024-03-20
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-5.14%
|
O:
-0.33%
H:
1.02%
C:
0.48%
opdivo
treatment
trial
advanced
plus
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
Published:
2024-02-22
(Crawled : 12:00)
- globenewswire.com
IMCR
|
$57.32
2.69%
2.62%
300K
|
Manufacturing
|
-20.53%
|
O:
0.91%
H:
0.95%
C:
-2.05%
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-3.48%
|
O:
-0.65%
H:
1.63%
C:
1.48%
melanoma
nivolumab
collaboration
trial
advanced
agreement
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published:
2023-12-12
(Crawled : 08:00)
- biospace.com/
TSVT
|
$4.63
-0.43%
-0.43%
290K
|
|
43.96%
|
O:
-4.02%
H:
9.35%
C:
4.84%
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-3.82%
|
O:
-0.57%
H:
0.28%
C:
-0.57%
therapy
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published:
2023-12-07
(Crawled : 18:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-1.48%
|
O:
0.84%
H:
1.39%
C:
-0.28%
opdivo
trial
plus
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published:
2023-10-30
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-3.68%
|
O:
1.39%
H:
0.32%
C:
-0.93%
KPTI
|
$1.085
-3.98%
-4.15%
1.6M
|
Health Technology
|
37.09%
|
O:
2.92%
H:
6.08%
C:
-3.35%
collaboration
trial
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published:
2023-10-23
(Crawled : 11:00)
- globenewswire.com
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-12.96%
|
O:
-0.19%
H:
0.66%
C:
-0.62%
ADXS
|
$0.572
12.48%
270
|
Health Technology
|
-36.67%
|
O:
0.0%
H:
5.56%
C:
0.0%
al102
congress
tumors
pharmaceuticals
trial
results
phase 2
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Published:
2023-10-19
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-13.56%
|
O:
-0.37%
H:
0.56%
C:
-0.28%
nivolumab
renal
cell
trial
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Published:
2023-10-17
(Crawled : 00:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-14.05%
|
O:
-0.03%
H:
0.87%
C:
0.38%
lung
opdivo
cancer
cell
trial
benefits
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Published:
2023-10-17
(Crawled : 00:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-14.05%
|
O:
-0.03%
H:
0.87%
C:
0.38%
lung
opdivo
cancer
cell
trial
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Published:
2023-10-06
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-12.9%
|
O:
-0.3%
H:
1.12%
C:
0.73%
trials
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published:
2023-09-11
(Crawled : 14:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-19.2%
|
O:
-0.12%
H:
1.11%
C:
0.1%
lung
opdivo
cancer
cell
treatment
trial
plus
show
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Published:
2023-08-28
(Crawled : 19:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-20.84%
|
O:
-0.03%
H:
0.56%
C:
-0.68%
camzyos
response
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published:
2023-08-16
(Crawled : 18:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-20.42%
|
O:
-0.66%
H:
0.46%
C:
-0.67%
lung
cancer
cell
trial
show
benefits
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and PFS Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
Published:
2023-07-11
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-21.35%
|
O:
-0.26%
H:
0.96%
C:
0.75%
opdivo
trial
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma
Published:
2023-06-27
(Crawled : 22:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-24.15%
|
O:
-0.06%
H:
0.46%
C:
0.0%
fotivda
renal
cell
study
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published:
2023-06-16
(Crawled : 10:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-24.01%
|
O:
0.32%
H:
2.1%
C:
1.97%
camzyos
drug
label
food
positive
study
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
Published:
2023-05-22
(Crawled : 21:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-25.36%
|
O:
0.0%
H:
0.7%
C:
-0.05%
lung
fibrosis
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
Published:
2023-03-30
(Crawled : 15:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-27.93%
|
O:
0.29%
H:
0.22%
C:
-0.26%
lung
opdivo
cancer
cell
trial
benefits
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published:
2023-03-23
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-26.92%
|
O:
0.52%
H:
0.46%
C:
-0.9%
BBIO
|
$25.43
1.44%
1.42%
1.1M
|
Health Technology
|
95.25%
|
O:
0.62%
H:
5.65%
C:
5.11%
bbp-398
opdivo
lung
pharma
cancer
trial
phase 1
← Previous
1
2
3
4
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
M
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.